Anticancer research · 2003
Photodynamic therapy for sarcoma pulmonary metastases: a preclinical toxicity study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Anderson Timothy M, Dougherty Thomas J, Tan Dongfeng, Sumlin Adam, Schlossin Joanne M, Kanter Peter M
Аннотация
BACKGROUND: Intraoperative pleural and interstitial PDT accompanying resection may reduce peripheral micrometastatic foci and preclude lobectomy when applied to hilar lesions.
MATERIALS AND METHODS: Fourteen beagles were used to determine the safety and histologic changes resulting from PDT. Photosensitizers HPPH (0.3 mg/kg) or Photofrin (2.0 mg/kg) were administered i.v. 48 hours prior to thoracotomy and light delivery. At thoracotomy interstitial or pleural light was given. They underwent necropsy at eight and 30 days.
RESULTS: The significant toxicitities occurred with pleural PDT using high dose HPPH (15 & 30 J/cm2) including pyrexia, elevated WBC and CPK, and respiratory distress. However, using single beam pleural surface treatment all light doses for HPPH and Photofrin (5-40 J/cm2) were tolerated with depths of treatment effect up to 10 mm with HPPH.
CONCLUSION: Histologic and clinical changes associated with interstitial and pleural PDT were acceptable after dosimetry was adjusted. PDT holds promise as an adjuvant treatment for sarcoma pulmonary metastases.
MATERIALS AND METHODS: Fourteen beagles were used to determine the safety and histologic changes resulting from PDT. Photosensitizers HPPH (0.3 mg/kg) or Photofrin (2.0 mg/kg) were administered i.v. 48 hours prior to thoracotomy and light delivery. At thoracotomy interstitial or pleural light was given. They underwent necropsy at eight and 30 days.
RESULTS: The significant toxicitities occurred with pleural PDT using high dose HPPH (15 & 30 J/cm2) including pyrexia, elevated WBC and CPK, and respiratory distress. However, using single beam pleural surface treatment all light doses for HPPH and Photofrin (5-40 J/cm2) were tolerated with depths of treatment effect up to 10 mm with HPPH.
CONCLUSION: Histologic and clinical changes associated with interstitial and pleural PDT were acceptable after dosimetry was adjusted. PDT holds promise as an adjuvant treatment for sarcoma pulmonary metastases.